神経障害発現に及ぼすシスプラチン分割投与の影響

概要

論文の詳細を見る
Several methods have been tried in reducing the adverse effects of chemotherapy, one of them divided dose schedules for chemotherapy agents. In the present study, we evaluated the impact of a divided dose schedule for cisplatin (CDDP) on the development of peripheral neuropathy. The study subjects were 7 Non Small Lung Cancer patients who developed peripheral neuropathy. All patients treated received CIC therapy (CDDP : 20mg/m^2, day 1-4, ifosfamide : 1500mg/m^2, day 1-4, irinotecan : 60mg/m^2, day 1, 8, 15) according to a divided dose schedule. We based our neuropathy evaluation on the medical records, medication history and nursing records of these subjects. As for neuropathy symptoms, there were 6 cases of numbness and one case of distal paresthesia in the hands or legs, which were considered to be caused by CDDP. Peripheral neuropathy is generally expected to occur after the administration of approximately 300mg/m^2 of CDDP. In our study, the mean total dose of CDDP was 330.1±67.3mg/m^2, that for ifosfamide 25716.8±6013.1mg/m^2 and that for irinotecan 662.3±158.0mg/m^2. The conclusion of our study was that peripheral neuropathy occurred after the administration of approximately 300mg/m^2 of CDDP for both the conventional and divided dose schedules.
日本医療薬学会の論文
2006-01-10